NO20006645L - Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme - Google Patents
Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den sammeInfo
- Publication number
- NO20006645L NO20006645L NO20006645A NO20006645A NO20006645L NO 20006645 L NO20006645 L NO 20006645L NO 20006645 A NO20006645 A NO 20006645A NO 20006645 A NO20006645 A NO 20006645A NO 20006645 L NO20006645 L NO 20006645L
- Authority
- NO
- Norway
- Prior art keywords
- irbesartan
- obtaining
- same
- pharmaceutical preparations
- preparations containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9808037A FR2780403B3 (fr) | 1998-06-24 | 1998-06-24 | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
PCT/FR1999/001372 WO1999067236A1 (fr) | 1998-06-24 | 1999-06-10 | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20006645D0 NO20006645D0 (no) | 2000-12-22 |
NO20006645L true NO20006645L (no) | 2001-02-26 |
NO317786B1 NO317786B1 (no) | 2004-12-13 |
Family
ID=9527829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20006645A NO317786B1 (no) | 1998-06-24 | 2000-12-22 | Ny form av irbesartan, fremgangsmate for a oppna den nevnte form og farmasoytiske preparater inneholdende den samme |
Country Status (25)
Country | Link |
---|---|
US (2) | US6800761B1 (no) |
EP (1) | EP1089994B9 (no) |
JP (1) | JP2002518495A (no) |
KR (1) | KR20010034917A (no) |
CN (1) | CN1127499C (no) |
AT (1) | ATE275562T1 (no) |
AU (1) | AU747887B2 (no) |
BG (1) | BG105069A (no) |
BR (1) | BR9912198A (no) |
CA (1) | CA2335545A1 (no) |
CZ (1) | CZ292868B6 (no) |
DE (1) | DE69920017T2 (no) |
EA (1) | EA003410B1 (no) |
FR (1) | FR2780403B3 (no) |
HU (1) | HUP0103913A3 (no) |
ID (1) | ID27377A (no) |
IL (1) | IL140419A0 (no) |
NO (1) | NO317786B1 (no) |
NZ (1) | NZ508842A (no) |
PL (1) | PL345215A1 (no) |
SK (1) | SK20032000A3 (no) |
TR (1) | TR200003842T2 (no) |
UA (1) | UA55540C2 (no) |
WO (1) | WO1999067236A1 (no) |
ZA (1) | ZA200007588B (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2469656A1 (en) * | 2001-12-10 | 2003-06-19 | Dr. Reddy's Laboratories Limited | Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one |
CN101165062A (zh) | 2003-01-16 | 2008-04-23 | 特瓦制药工业有限公司 | 伊贝沙坦的新合成方法 |
GB0301259D0 (en) * | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
AU2007202693B2 (en) * | 2003-01-20 | 2009-12-10 | Novartis Ag | Process for modifying drug crystal formation |
EP1590343B1 (en) * | 2003-02-05 | 2008-07-16 | Teva Pharmaceutical Industries Limited | Synthesis of 2-butyl-3-(2' -(1-trityl-1h-tetrazol-5-yl)biphen yl-4-yl)-1,3-diazaspiro-4,4 -nonene-4-one |
AU2004268983A1 (en) * | 2003-08-27 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Cycloalkylaminoacid compounds, processes for making and uses thereof |
EP1751123A4 (en) * | 2004-05-20 | 2010-06-30 | Reddys Lab Ltd Dr | PROCESS FOR PREPARING IRBESARTAN |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
SI21849A (sl) * | 2004-07-29 | 2006-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava hidrokloridnih soli tetrazolskega derivata |
SI21848A (sl) * | 2004-07-29 | 2006-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata |
TWI346108B (en) | 2004-08-23 | 2011-08-01 | Bristol Myers Squibb Co | A method for preparing irbesartan and intermediates thereof |
GB2419592A (en) * | 2004-10-26 | 2006-05-03 | Cipla Ltd | Process for the preparation of irbesartan hydrochloride |
EP1812422B1 (en) | 2004-11-11 | 2013-12-25 | LEK Pharmaceuticals d.d. | Polymorph form of irbesartan |
PT1806130E (pt) | 2006-01-09 | 2010-05-11 | Krka D D Novo Mesto | Composições farmacêuticas sólidas que compreendem irbesartan |
WO2008041957A1 (en) * | 2006-10-03 | 2008-04-10 | Ulkar Kimya Sanayi Ve Ticaret As | Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one |
ES2315141B1 (es) * | 2006-11-23 | 2009-12-22 | Quimica Sintetica, S.A | Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina. |
RU2465900C2 (ru) * | 2007-04-17 | 2012-11-10 | Рациофарм Гмбх | Фармацевтические композиции, содержащие ирбесартан |
PT2200606T (pt) * | 2007-09-10 | 2017-12-13 | Janssen Pharmaceutica Nv | Processo para a preparação de compostos úteis como inibidores de sglt |
EP2065035B1 (en) | 2007-11-28 | 2010-07-21 | Laboratorios Lesvi, S.L. | Pharmaceutical formulations containing irbesartan |
EP2215083A2 (en) * | 2007-12-07 | 2010-08-11 | Hetero Drugs Limited | Process for pure irbesartan |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
CZ302407B6 (cs) * | 2009-03-12 | 2011-05-04 | Univerzita Pardubice | Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
WO2011003976A1 (en) * | 2009-07-10 | 2011-01-13 | Janssen Pharmaceutica Nv | CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE |
AR078107A1 (es) * | 2009-08-31 | 2011-10-12 | Sanofi Aventis | Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca |
CA2777528C (en) * | 2009-10-14 | 2018-09-18 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
WO2011143296A1 (en) | 2010-05-11 | 2011-11-17 | Janssen Pharmaceutica Nv | Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
PL2697218T3 (pl) | 2011-04-13 | 2016-11-30 | Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2 | |
TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
CA3006237C (en) * | 2015-12-21 | 2023-10-03 | Janssen Pharmaceutica Nv | Crystallization procedure for obtaining canagliflozin hemihydrate crystals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270317A (en) | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
IE910913A1 (en) * | 1990-03-20 | 1991-09-25 | Sanofi Sa | N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them |
FR2725987B1 (fr) | 1994-10-19 | 1997-01-10 | Sanofi Sa | Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive |
-
1998
- 1998-06-24 FR FR9808037A patent/FR2780403B3/fr not_active Expired - Lifetime
-
1999
- 1999-06-10 IL IL14041999A patent/IL140419A0/xx unknown
- 1999-06-10 AT AT99923712T patent/ATE275562T1/de not_active IP Right Cessation
- 1999-06-10 JP JP2000555889A patent/JP2002518495A/ja active Pending
- 1999-06-10 BR BR9912198-0A patent/BR9912198A/pt not_active IP Right Cessation
- 1999-06-10 WO PCT/FR1999/001372 patent/WO1999067236A1/fr active IP Right Grant
- 1999-06-10 EP EP99923712A patent/EP1089994B9/fr not_active Revoked
- 1999-06-10 SK SK2003-2000A patent/SK20032000A3/sk unknown
- 1999-06-10 US US09/720,017 patent/US6800761B1/en not_active Expired - Lifetime
- 1999-06-10 CA CA002335545A patent/CA2335545A1/en not_active Abandoned
- 1999-06-10 ID IDW20002738A patent/ID27377A/id unknown
- 1999-06-10 PL PL99345215A patent/PL345215A1/xx not_active Application Discontinuation
- 1999-06-10 EA EA200001221A patent/EA003410B1/ru not_active IP Right Cessation
- 1999-06-10 NZ NZ508842A patent/NZ508842A/xx unknown
- 1999-06-10 TR TR2000/03842T patent/TR200003842T2/xx unknown
- 1999-06-10 KR KR1020007014640A patent/KR20010034917A/ko active IP Right Grant
- 1999-06-10 CN CN99807707A patent/CN1127499C/zh not_active Expired - Fee Related
- 1999-06-10 AU AU40484/99A patent/AU747887B2/en not_active Ceased
- 1999-06-10 DE DE69920017T patent/DE69920017T2/de not_active Revoked
- 1999-06-10 CZ CZ20004771A patent/CZ292868B6/cs not_active IP Right Cessation
- 1999-06-10 HU HU0103913A patent/HUP0103913A3/hu unknown
- 1999-10-06 UA UA2000127044A patent/UA55540C2/uk unknown
-
2000
- 2000-12-18 ZA ZA200007588A patent/ZA200007588B/en unknown
- 2000-12-19 BG BG105069A patent/BG105069A/xx unknown
- 2000-12-22 NO NO20006645A patent/NO317786B1/no not_active IP Right Cessation
-
2004
- 2004-09-09 US US10/937,467 patent/US7008959B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20006645L (no) | Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme | |
NO991732L (no) | Nye heterocyklylmetylsubstituerte pyrazolderivater | |
NO992400L (no) | Nye substituerte pyrazolderivater | |
ATE255589T1 (de) | Kristallin form i von clarithromycin | |
DK1200418T3 (da) | Nematodicide trifluorbutener | |
DE60022230D1 (de) | Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv | |
MXPA03001463A (es) | Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen. | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
RS19504A (en) | Novel compounds and compositions as cathepsin inhibitors | |
PL336640A1 (en) | Substituted 3,3-diamino-2- propenonitriles, their production and application | |
MXPA03001536A (es) | (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen. | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
DE69926223D1 (de) | Verfahren zur herstellung von zwischenprodukten | |
DE69718500D1 (de) | (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen | |
DE69717844D1 (de) | Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen | |
ATE421961T1 (de) | Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält | |
NO20031137D0 (no) | Fremgangsmåte for fremstilling av kirale forbindelser | |
BG107553A (en) | Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same | |
MEP56208A (en) | Caloporoside derivatives, methods for the production thereof and their use | |
NO20010122L (no) | Fremgangsmåte for stereoselektiv fremstilling av Grignard- forbindelser og anvendelse derav | |
RO116896B1 (ro) | Derivaţi pseudocarbaciclinici şi procedeu pentru prepararea acestora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |